KCG Holdings Inc. Buys New Stake in NxStage Medical, Inc. (NASDAQ:NXTM)

KCG Holdings Inc. purchased a new position in shares of NxStage Medical, Inc. (NASDAQ:NXTM) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,903 shares of the medical device company’s stock, valued at approximately $293,000.

Other hedge funds also recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of NxStage Medical during the first quarter worth about $140,000. Ameritas Investment Partners Inc. acquired a new position in shares of NxStage Medical during the first quarter worth about $148,000. Menta Capital LLC acquired a new position in shares of NxStage Medical during the first quarter worth about $212,000. Trexquant Investment LP acquired a new position in shares of NxStage Medical during the first quarter worth about $227,000. Finally, Karp Capital Management Corp acquired a new position in shares of NxStage Medical during the first quarter worth about $256,000. 91.11% of the stock is owned by institutional investors and hedge funds.

Shares of NxStage Medical, Inc. (NXTM) opened at 29.22 on Friday. The firm’s market capitalization is $1.93 billion. The firm has a 50-day moving average of $24.92 and a 200 day moving average of $25.85. NxStage Medical, Inc. has a 52 week low of $20.45 and a 52 week high of $30.80.

NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm had revenue of $92.20 million during the quarter, compared to analyst estimates of $96.47 million. During the same quarter in the prior year, the firm earned ($0.03) EPS. The business’s revenue for the quarter was up .0% compared to the same quarter last year. On average, equities analysts predict that NxStage Medical, Inc. will post ($0.04) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/08/12/10903-shares-in-nxstage-medical-inc-nasdaqnxtm-acquired-by-kcg-holdings-inc-updated-updated.html.

A number of equities analysts have recently weighed in on NXTM shares. BidaskClub raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. Craig Hallum started coverage on shares of NxStage Medical in a research report on Tuesday, June 27th. They set a “buy” rating and a $32.00 price target on the stock. Jefferies Group LLC reduced their price target on shares of NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, May 10th. BTIG Research reissued a “buy” rating and set a $27.00 price target on shares of NxStage Medical in a research report on Wednesday, May 10th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $32.00 price objective on shares of NxStage Medical in a research report on Monday, May 8th. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $30.29.

In related news, SVP Matthew W. Towse sold 4,300 shares of the stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $21.36, for a total value of $91,848.00. Following the completion of the sale, the senior vice president now directly owns 29,637 shares of the company’s stock, valued at approximately $633,046.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $21.94, for a total transaction of $76,790.00. Following the sale, the senior vice president now directly owns 17,770 shares of the company’s stock, valued at $389,873.80. The disclosure for this sale can be found here. Insiders have sold a total of 53,900 shares of company stock valued at $1,404,073 in the last ninety days. Insiders own 4.70% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

What are top analysts saying about NxStage Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NxStage Medical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit